Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers

References

• VogelmeierC, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2019 report. Available from: www.goldcopd.org. Accessed 929, 2020.
   Google Scholar
• UsmaniOS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472. doi:10.2147/TCRM.S16036530936708
   PubMed Web of Science ®Google Scholar
• DalbyRN, EicherJ, ZierenbergB. Development of respimat® soft mist™ inhaler and its clinical utility in respiratory disorders. Med Devices. 2011;4:145–155.
   Google Scholar
• GhoshS, OharJA, DrummondMB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry power inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30(6):381–387. doi:10.1089/jamp.2017.141628933581
   PubMed Web of Science ®Google Scholar
• AndersonP. Use of respimat® soft mist™ inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1:251–259.18046862
   PubMedGoogle Scholar
• PitcairnG, ReaderS, PaviaD, NewmanS. Deposition of corticosteroid aerosol in the human lung by respimat soft mist™ inhaler compared to deposition by metered dose inhaler or by turbuhaler dry powder inhaler. J Aerosol Med. 2005;18:264–272. doi:10.1089/jam.2005.18.26416181001
   PubMedGoogle Scholar
• HohlfeldJM, SharmaA, van NoordJA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54:405–414. doi:10.1002/jcph.21524165906
   PubMed Web of Science ®Google Scholar
• KarnerC, ChongJ, PooleP. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;7:CD009285.
   Google Scholar
• KeatingGM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72:273–300. doi:10.2165/11208620-000000000-0000022217233
   PubMed Web of Science ®Google Scholar
• KeatingGM. Tiotropium respimat® soft mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74(15):1801–1816. doi:10.1007/s40265-014-0307-425300412
   PubMed Web of Science ®Google Scholar
• WiseRA, AnzuetoA, CalverleyP, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial—design and rationale. Respir Res. 2013;14:40. doi:10.1186/1465-9921-14-4023547660
   PubMed Web of Science ®Google Scholar
• SchmiedlS, FischerR, IbanezL, et al. Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability. Br J Clin Pharmacol. 2016;81(2):379–388. doi:10.1111/bcp.1280826506314
   PubMed Web of Science ®Google Scholar
• Spila-AligianiS, TrottaF, Da CasR, RossiM, VenegoniM, TraversaG. Comparative effectiveness of two tiotropium formulations: a retrospective cohort study. COPD. 2018;15(5):418–423. doi:10.1080/15412555.2018.155403230822243
   PubMedGoogle Scholar
• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global burden of Disease Study 2015. Lancet. 2017;5(9):691–706.
   Web of Science ®Google Scholar
• BlanchetteCM, GrossNJ, AltmanP. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 2014;7(2):98–106.24991394
   PubMedGoogle Scholar
• US Department of Commerce. US census bureau. Census regions and divisions of the United States. Available from: https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf. Accessed 102, 2019.
   Google Scholar
• QuanH, LiB, CourisCM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq43321330339
   PubMed Web of Science ®Google Scholar
• WuEQ, BirnbaumHG, CifaldiM, et al. Development of a COPD severity score. Curr Med Res Opin. 2006;22(9):1679–1687. doi:10.1185/030079906X11562116968571
   PubMed Web of Science ®Google Scholar
• Department of Veterans Affairs and Department of Defense. VA/DoD clinical practice guideline for the management of chronic obstructive pulmonary disease. 2014 Available from: https://www.healthquality.va.gov/guidelines/CD/copd/. Accessed 929, 2020.
   Google Scholar
• U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Medical Care. Series ID: CUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics, 2018 Available from: http://data.bls.gov/cgi-bin/surveymost?cu. Accessed 1117, 2020.
   Google Scholar
• Yale New Haven Health Services Corporation/Center for Outcomes Research and Evaluation. 2013 measure updates and specifications report: hospital-level 30-day readmission following admission for an acute exacerbation of chronic obstructive pulmonary disease (version 2.0). 3, 2013 Available from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology. Accessed 716, 2020.
   Google Scholar
• RobinsJM. Marginal Structural Models. In ASA Proceedings in the Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association; 1997:1–10.
   Google Scholar
• RobinsJM, HernanMA, BrumbackB. Marginal structural models and causal inference in epidemiology. Epidemiol. 2000;11(5):550–560. doi:10.1097/00001648-200009000-00011
   PubMed Web of Science ®Google Scholar
• AustinPC, StuartEA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.660726238958
   PubMed Web of Science ®Google Scholar
• BollmeierSG, HartmannAP. Management of chronic obstructive pulmonary disease: a review focusing on exacerbations. Am J Health Syst Pharm. 2020;77(4):259–268. doi:10.1093/ajhp/zxz30631930287
   PubMed Web of Science ®Google Scholar
• ShahT, ChurpekMM, Coca PerraillonM, KonetzkaRT. Understanding why patients with COPD get readmitted: a large national study to delineate the medicare population for the readmissions penalty expansion. Chest. 2015;147(5):1219–1226. doi:10.1378/chest.14-218125539483
   PubMed Web of Science ®Google Scholar
• RinneST, CastanedaJ, LindenauerPK, ClearyPD, PazHL, GomezJL. Chronic obstructive pulmonary disease readmissions and other measures of hospital quality. Am J Respir Crit Care Med. 2017;196(1):47–55. doi:10.1164/rccm.201609-1944OC28145726
   PubMed Web of Science ®Google Scholar
• CMS.gov. Quality Net: Hospital Readmissions Reduction Program (HRRP). Available from: https://www.qualitynet.org/inpatient/hrrp. Accessed 716, 2020.
   Google Scholar
• WiseR, CalverleyPM, DahlR, et al. Safety and efficacy of tiotropium respimat versus HandiHaler in patients naïve to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. NPJ Prim Care Respir Med. 2015;25:15067. doi:10.1038/npjpcrm.2015.6726540491
   PubMed Web of Science ®Google Scholar
• PahusL, BurgelP-R, RochN, et al. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm Med. 2019;19(1):127. doi:10.1186/s12890-019-0882-y31299936
   PubMed Web of Science ®Google Scholar
• SchichiloneN, BasileM, BattagliaS, BelliaV. What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials? Respiration. 2014;87(1):11–17. doi:10.1159/00035508224281343
   PubMed Web of Science ®Google Scholar
• TrottaF, Spila AlegianiS, Da CasR, et al. Cardiovascular safety of tiotropium respimat vs HandiHaler in the routine clinical practice: a population-based cohort study. PLoS One. 2017;2(4):e0176276. doi:10.1371/journal.pone.0176276
   Web of Science ®Google Scholar